

Arix Bioscience Plc (ARIX) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/A0F499B08A4EN.html>

Date: November 2018

Pages: 59

Price: US\$ 125.00 (Single User License)

ID: A0F499B08A4EN

Abstracts

Arix Bioscience Plc (ARIX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Arix Bioscience Plc (Arix Bioscience), formerly Perceptive Bioscience Investments Ltd invests exclusively in diverse healthcare and life science companies. The company sources, and finances the companies for accelerating the commercialization of their novel medical innovations. Its investment portfolio encompasses companies that develop therapies to address the unmet medical need of oncology, infectious diseases, orphan diseases, and gene therapies. It works in collaboration with universities, research institutions, and biopharmaceutical companies for advancing new technologies. The company serves both public and private sector companies. It has subsidiaries in Australia, Scotland, the US, and the UK. Arix Bioscience is headquartered in London, the UK.

Arix Bioscience Plc Key Recent Developments

Nov 15,2018: Arix Bioscience plc: Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for Second LOXL2 Inhibitor Compound

Oct 11,2018: Arix Bioscience plc: Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for LOXL2 Inhibitor Compound

Sep 26,2018: Fred Hutch launches business partnership: LAB591

Sep 12,2018: ARIX Bioscience announces Board Changes, appointment of Arthur

Pappas to the Board of Directors, David U'Prichard to retire from Board
Sep 04,2018: Arix Bioscience: Changes announced to executive team to accelerate growth and strategy

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Arix Bioscience Plc - Key Facts
Arix Bioscience Plc - Key Employees
Arix Bioscience Plc - Key Employee Biographies
Arix Bioscience Plc - Key Operational Employees
Arix Bioscience Plc - Major Products and Services
Arix Bioscience Plc - History
Arix Bioscience Plc - Company Statement
Arix Bioscience Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Arix Bioscience Plc - Business Description
Arix Bioscience Plc - Corporate Strategy
Arix Bioscience Plc - SWOT Analysis
SWOT Analysis - Overview
Arix Bioscience Plc - Strengths
Arix Bioscience Plc - Weaknesses
Arix Bioscience Plc - Opportunities
Arix Bioscience Plc - Threats
Arix Bioscience Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Arix Bioscience Plc, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Nov 15, 2018: Arix Bioscience plc: Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for Second LOXL2 Inhibitor Compound

Nov 15, 2018: Arix Bioscience plc: Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for Second LOXL2 Inhibitor Compound

Oct 11, 2018: Arix Bioscience plc: Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for LOXL2 Inhibitor Compound

Oct 11, 2018: Arix Bioscience plc: Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for LOXL2 Inhibitor Compound

Sep 26, 2018: Fred Hutch launches business partnership: LAB591

Sep 12, 2018: ARIX Bioscience announces Board Changes, appointment of Arthur Pappas to the Board of Directors, David U'Prichard to retire from Board

Sep 04, 2018: Arix Bioscience: Changes announced to executive team to accelerate growth and strategy

May 31, 2018: Arix Bioscience Forms Strategic Collaboration with Evotec AG and Fred Hutchinson Cancer Research Center to Foster New Companies in Cancer and Infectious Diseases

May 31, 2018: Evotec forms academic BRIDGE 'LAB591' with Arix Bioscience and Fred Hutchinson Cancer Research Center

May 08, 2018: Arix Bioscience plc: Autolus Files for Proposed Initial Public Offering in the United States

SECTION 5 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Arix Bioscience Plc, Key Facts
Arix Bioscience Plc, Key Employees
Arix Bioscience Plc, Key Employee Biographies
Arix Bioscience Plc, Key Operational Employees
Arix Bioscience Plc, Major Products and Services
Arix Bioscience Plc, History
Arix Bioscience Plc, Other Locations
Arix Bioscience Plc, Subsidiaries
Arix Bioscience Plc, Key Competitors
Arix Bioscience Plc, Ratios based on current share price
Arix Bioscience Plc, Annual Ratios
Arix Bioscience Plc, Annual Ratios (Cont.1)
Arix Bioscience Plc, Interim Ratios
Arix Bioscience Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Arix Bioscience Plc, Performance Chart (2016 - 2017)

Arix Bioscience Plc, Ratio Charts

COMPANIES MENTIONED

Albion Venture Capital Trust plc

Woodford Patient Capital Trust plc

TEXO Ventures

Syncona Limited

Alacrita LLP

Insight Venture Partners, LLC

Abingworth LLP

Kings Arms Yard VCT PLC

Crown Place VCT Plc

Advent Life Sciences LLP

I would like to order

Product name: Arix Bioscience Plc (ARIX) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/A0F499B08A4EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A0F499B08A4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970